Literature DB >> 8363349

Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels.

B J Snow1, I Tooyama, E G McGeer, T Yamada, D B Calne, H Takahashi, H Kimura.   

Abstract

Postmortem counts of dopaminergic cell densities in the substantia nigra (5 subjects) and striatal levels of dopamine (DA) and its metabolites (6 subjects) were determined on 1 parkinsonian (PD), 3 progressive supranuclear palsy (PSP), 1 amyotrophic lateral sclerosis, and 1 Alzheimer's case who had been positron emission tomography scanned with 6-[18F]fluorodopa during life. [18F]Fluorodopa uptake rate constants, which presumably depend on the number of functioning striatal DA terminals, were strictly proportional to cell densities (significant correlation with zero intercept) and also correlated significantly with striatal DA levels but with an intercept indicating greater losses of DA than of terminals in PSP and PD. Postmortem data on 6 PD, 1 PSP, and 9 neuronally normal controls substantiated the significant correlation between cell counts and DA levels, with the latter being the more depressed in pathological cases.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8363349     DOI: 10.1002/ana.410340304

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  41 in total

Review 1.  Neuroimaging biomarkers for Parkinson disease: facts and fantasy.

Authors:  Joel S Perlmutter; Scott A Norris
Journal:  Ann Neurol       Date:  2014-11-07       Impact factor: 10.422

Review 2.  Applications of positron emission tomography (PET) in neurology.

Authors:  Y F Tai; P Piccini
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

Review 3.  The development, past achievements, and future directions of brain PET.

Authors:  Terry Jones; Eugenii A Rabiner
Journal:  J Cereb Blood Flow Metab       Date:  2012-03-21       Impact factor: 6.200

4.  Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration.

Authors:  David S Goldstein; Courtney Holmes; Patti Sullivan; Deborah C Mash; Ellen Sidransky; Alessandro Stefani; Irwin J Kopin; Yehonatan Sharabi
Journal:  Parkinsonism Relat Disord       Date:  2015-07-17       Impact factor: 4.891

Review 5.  Neuroimaging in Parkinson's disease.

Authors:  David J Brooks
Journal:  NeuroRx       Date:  2004-04

6.  Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.

Authors:  P K Morrish; J S Rakshi; D L Bailey; G V Sawle; D J Brooks
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-03       Impact factor: 10.154

7.  (18)F-DOPA PET with and without MRI fusion, a receiver operator characteristics comparison.

Authors:  Aaron F Struck; Lance T Hall; Joanna E Kusmirek; Catherine L Gallagher; John M Floberg; Christine J Jaskowiak; Scott B Perlman
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-10-15

8.  Clinical and neuroimaging characteristics in neurodegenerative overlap syndrome.

Authors:  Young-Min Lim; Hee Kyung Park; Jae Seung Kim; Chong Sik Lee; Sun Ju Chung; Jimin Kim; Kwang-Kuk Kim
Journal:  Neurol Sci       Date:  2012-06-28       Impact factor: 3.307

9.  Validation of nigrostriatal positron emission tomography measures: critical limits.

Authors:  Morvarid Karimi; LinLin Tian; Christopher A Brown; Hubert P Flores; Susan K Loftin; Tom O Videen; Stephen M Moerlein; Joel S Perlmutter
Journal:  Ann Neurol       Date:  2013-02-19       Impact factor: 10.422

Review 10.  Surrogate endpoints in Parkinson's disease research.

Authors:  Kevin M Biglan; Robert G Holloway
Journal:  Curr Neurol Neurosci Rep       Date:  2003-07       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.